MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026 WITH INDEPENDENT AUDITOR'S REVIEW REPORT

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
FOR THE THREE AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026

INDEX **PAGE**

Independent auditor's report on review of condensed consolidated interim financial statements	-
Condensed consolidated statement of financial position	1
Condensed consolidated statement of profit or loss and other comprehensive income	2 – 3
Condensed consolidated statement of changes in equity	4
Condensed consolidated statement of cash flows	5 – 6
Notes to the condensed consolidated interim financial statements	7 – 20

KPMG Professional Services Company
16th Floor, Al Barghash Tower
6189 Prince Turki Road, Al Corniche
P.O. Box 4803
Al Khobar, 34412 - 3146
Kingdom of Saudi Arabia
Commercial Registration No 2051062328

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية
الطابق ١٦، برج البرغش
٦١٨٩ طريق الأمير تركي، الكورنيش
ص.ب ٤٨٠٣
الخبر ٣٤٤١٢ - ٣١٤٦
المملكة العربية السعودية
سجل تجاري رقم ٢٠٥١٠٦٢٣٢٨

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 September 2026 condensed consolidated interim financial statements of **Mouwasat Medical Services Company** ("the Company") and its subsidiaries ("the Group") which comprises:

- the condensed consolidated statement of financial position as at 30 September 2026;
- the condensed consolidated statement of profit or loss and other comprehensive income for the three and nine-month periods ended 30 September 2026;
- the condensed consolidated statement of changes in equity for the nine-month period ended 30 September 2026;
- the condensed consolidated statement of cash flows for the nine-month period ended 30 September 2026; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of condensed consolidated interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

© 2026 KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR110,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

©٢٠٢٦ شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية، شركة مساهمة مهنية مقفلة مسجلة في المملكة العربية السعودية، رأس مالها (١١٠،٠٠٠،٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير شريك في الشبكة العالمية لشركات كي بي إم جي المستقلة والتابعة لـ كي بي إم جي العالمية المحدودة، شركة انجليزية خاصة محدودة بالضمان. جميع الحقوق محفوظة.

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Mouwasat Medical Services Company (A Saudi Joint Stock Company) (continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2026 condensed consolidated interim financial statements of **Mouwasat Medical Services Company and its subsidiaries** are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services Company





Mohammed Najeeb Alkhlaiwi
License no. 481

Al Khobar,
4 November 2026G
Corresponding to: 24 Jumada Al Oula 1448H

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 September 2026 (Unaudited)	31 December 2025 (Audited)
ASSETS			
Non-current assets			
Property and equipment	3	**4,564,495,633**	3,971,300,149
Goodwill		**16,371,000**	16,371,000
Intangible assets		**29,091,912**	30,631,152
Right-of-use asset	4.1	**65,983,943**	36,614,738
Lease receivable	4(b)	**801,892**	862,793
Advances to contractors and suppliers		**203,915,600**	192,545,770
Total non-current assets		**4,880,659,980**	4,248,325,602
Current assets			
Inventories		**288,617,604**	236,898,566
Accounts receivables	5	**1,036,123,093**	905,840,981
Advance to a related party	10	**3,859,810**	-
Current portion of lease receivable	4 (b)	**84,176**	141,000
Advances, prepayments and other current assets		**105,298,864**	97,610,627
Cash and cash equivalents		**393,707,341**	497,450,629
Total current assets		**1,827,690,888**	1,737,941,803
Total assets		**6,708,350,868**	5,986,267,405
EQUITY AND LIABILITIES			
Equity			
Share capital	6	**2,000,000,000**	2,000,000,000
Other reserve	16	**512,548,823**	512,548,823
Retained earnings		**1,640,851,501**	1,265,455,162
Equity attributable to shareholders of the Company		**4,153,400,324**	3,778,003,985
Non-controlling interest		**152,608,662**	142,533,453
Total equity		**4,306,008,986**	3,920,537,438
Liabilities			
Non-current liabilities			
Long-term borrowings	7	**1,004,970,260**	757,150,409
Employees' benefits		**226,237,407**	205,151,296
Lease liabilities	4.2	**52,663,253**	36,652,754
Retention payables		**57,050,955**	67,316,867
Total non-current liabilities		**1,340,921,875**	1,066,271,326
Current liabilities			
Accounts payable		**359,892,042**	318,801,368
Due to related parties	10	**331,350**	2,947,362
Refund liability	9.1	**197,673,611**	179,041,660
Accruals and other current liabilities		**285,155,070**	267,990,431
Current maturity of lease liabilities	4.2	**15,917,340**	4,768,426
Current portion of long-term borrowings	7	**181,568,607**	190,921,219
Provision for zakat	8	**20,881,987**	34,988,175
Total current liabilities		**1,061,420,007**	999,458,641
Total liabilities		**2,402,341,882**	2,065,729,967
Total equity and liabilities		**6,708,350,868**	5,986,267,405

Nassir Alsubaei	Khalid Al Saleem	Adel Abou Hamra
(Chief Executive Officer)	(Authorized Board Representative)	(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE THREE AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	For the three-month period ended		For the nine-month period ended	
		30 September 2026	30 September 2025	**30 September 2026**	30 September 2025
		(Unaudited)	(Unaudited)	**(Unaudited)**	(Unaudited)
Revenue					
Medical services revenue		**743,157,424**	658,712,723	**2,203,459,707**	1,987,753,053
Pharmaceutical sales		**113,207,684**	118,611,920	**363,146,752**	350,273,693
	9	**856,365,108**	777,324,643	**2,566,606,459**	2,338,026,746
Direct cost					
Cost of operations		**(435,899,340)**	(385,686,778)	**(1,277,479,762)**	(1,114,654,756)
Cost of sales		**(76,752,300)**	(82,993,130)	**(246,027,335)**	(239,957,905)
		(512,651,640)	(468,679,908)	**(1,523,507,097)**	(1,354,612,661)
Gross profit		**343,713,468**	308,644,735	**1,043,099,362**	983,414,085
Selling and marketing expenses		**(8,668,846)**	(14,573,702)	**(42,427,306)**	(43,682,077)
General and administration expenses		**(127,447,716)**	(104,236,892)	**(371,884,268)**	(333,555,202)
(Impairment) / reversal of loss on accounts receivables		**(6,647,687)**	19,450,000	**(16,960,367)**	15,740,995
Other income		**1,926,813**	2,945,905	**27,447,282**	7,002,482
Operating profit		**202,876,032**	212,230,046	**639,274,703**	628,920,283
Finance income		**3,783,737**	4,391,700	**9,456,313**	17,001,215
Finance cost		**(5,909,690)**	(4,574,087)	**(16,558,446)**	(15,716,812)
Profit before zakat		**200,750,079**	212,047,659	**632,172,570**	630,204,686
Zakat expense for the period	8	**(6,009,551)**	(4,957,188)	**(9,451,022)**	(23,594,266)
Profit for the period		**194,740,528**	207,090,471	**622,721,548**	606,610,420
Other comprehensive income					
Items that will not be reclassified to the condensed consolidated statement of profit or loss in subsequent periods:					
Re-measurement of defined benefit obligations		-	-	-	-
Other comprehensive income for the period		-	-	-	-
Total comprehensive income for the period		**194,740,528**	207,090,471	**622,721,548**	606,610,420

Nassir Alsubaei	Khalid Al Saleem	Adel Abou Hamra
(Chief Executive Officer)	(Authorized Board Representative)	(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONTINUED)
FOR THE THREE AND NINE-MONTH PERIODS ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	For the three-month period ended		For the nine-month period ended	
		30 September 2026	30 September 2025	**30 September 2026**	30 September 2025
		(Unaudited)	(Unaudited)	**(Unaudited)**	(Unaudited)
Profit attributable to:					
- **Shareholders of the Company**		**188,013,890**	199,657,372	**600,396,339**	583,670,787
- **Non–controlling interests**		**6,726,638**	7,433,099	**22,325,209**	22,939,633
		194,740,528	207,090,471	**622,721,548**	606,610,420
Total comprehensive income attributable to:					
- **Shareholders of the Company**		**188,013,890**	199,657,372	**600,396,339**	583,670,787
- **Non–controlling interests**		**6,726,638**	7,433,099	**22,325,209**	22,939,633
		194,740,528	207,090,471	**622,721,548**	606,610,420
Earnings per share					
Basic and diluted earnings per share attributable to the shareholders of the Company	11	**0.94**	1.00	**3.00**	2.92

Nassir Alsubaei
(Chief Executive Officer)

Khalid Al Saleem
(Authorized Board Representative)

Adel Abou Hamra
(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Attributable to shareholders of the Company					
	Share capital	**Statutory reserve**	**Retained earnings**	**Total**	**Non-controlling interests**	**Total equity**
As at 1 January 2025 (Audited)	2,000,000,000	430,344,695	1,137,993,239	3,568,337,934	145,232,079	3,713,570,013
Total comprehensive income for the period						
Profit for the period	-	-	583,670,787	583,670,787	22,939,633	606,610,420
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	583,670,787	583,670,787	22,939,633	606,610,420
Dividends (note 13)	-	-	(400,000,000)	(400,000,000)	-	(400,000,000)
Dividend paid to non-controlling interest	-	-	-	-	(24,500,000)	(24,500,000)
Additional capital contribution	-	-	-	-	4,900,000	4,900,000
As at 30 September 2025 (Unaudited)	2,000,000,000	430,344,695	1,321,664,026	3,752,008,721	148,571,712	3,900,580,433
As at 1 January 2026 (Audited)	**2,000,000,000**	**512,548,823**	**1,265,455,162**	**3,778,003,985**	**142,533,453**	**3,920,537,438**
Total comprehensive income for the period						
Profit for the period	-	-	**600,396,339**	**600,396,339**	**22,325,209**	**622,721,548**
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	**600,396,339**	**600,396,339**	**22,325,209**	**622,721,548**
Dividends (note 13)	-	-	**(225,000,000)**	**(225,000,000)**	-	**(225,000,000)**
Dividend paid to non-controlling interest	-	-	-	-	**(12,250,000)**	**(12,250,000)**
As at 30 September 2026 (Unaudited)	**2,000,000,000**	**512,548,823**	**1,640,851,501**	**4,153,400,324**	**152,608,662**	**4,306,008,986**

Nassir Alsubaei	Khalid Al Saleem	Adel Abou Hamra
(Chief Executive Officer)	(Authorized Board Representative)	(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Cash flows from operating activities			
Profit for the period		**622,721,548**	606,610,420
Adjustment for:			
Depreciation of property and equipment	3.2	**195,523,102**	177,652,711
Depreciation of right-of-use asset	4.1	**9,395,808**	2,497,936
Provision / (reversal) for allowance for expected credit losses	5	**16,960,367**	(15,740,995)
Amortization of intangible assets		**6,086,955**	5,431,572
Provision for employees' benefits		**34,493,082**	29,898,453
Finance cost		**16,558,446**	15,716,812
Interest income on term deposit		**(9,456,313)**	(17,001,215)
Property and equipment written off, net	3.2	**16,000**	1,612
Intangible assets written off		**307**	-
Interest income on lease receivable	4(b)	**(23,275)**	(11,015)
Gain on de-recognition for sub-lease		**-**	(780,368)
Provision of obsolete inventory		**-**	13,319,608
Gain on disposal of property and equipment		**(20,601,129)**	(1,313,821)
Zakat expense for the period	8	**9,451,022**	23,594,266
		881,125,920	839,875,976
Changes in:			
Accounts receivable		**(147,242,479)**	101,602,472
Advance to a related party		**(3,859,810)**	-
Advances, prepayments, and other current assets		**(6,947,015)**	(23,252,905)
Inventories		**(51,719,038)**	(32,575,561)
Retention payables		**(10,265,912)**	11,810,128
Accounts payable		**41,090,674**	(692,259)
Due to related parties		**(2,616,012)**	(1,846,114)
Accruals and other current liabilities		**17,164,147**	19,128,627
Refund liability		**18,631,951**	(18,516,212)
Cash generated from operating activities		**735,362,426**	895,534,152
Employees' benefits paid		**(13,406,971)**	(13,221,793)
Finance cost paid		**(44,218,206)**	(37,407,210)
Zakat paid	8	**(23,557,210)**	(30,263,885)
Net cash from operating activities		**654,180,039**	814,641,264
Cash flows from investing activities			
Purchase of property and equipment		**(447,749,377)**	(403,440,148)
Purchase of intangible assets		**(4,548,022)**	(14,110,579)
Proceeds from disposal of property and equipment		**51,337,771**	2,027,130
Advances to contractors and suppliers		**(352,508,702)**	(214,898,198)
Interest received on term deposit		**8,715,091**	16,348,243
Term deposits		**-**	(24,000,000)
Additional capital contribution in subsidiary		**-**	4,900,000
Rent received from sub-lease		**141,000**	70,500
Net cash used in investing activities		**(744,612,239)**	(633,103,052)

Nassir Alsubaei	Khalid Al Saleem	Adel Abou Hamra
(Chief Executive Officer)	(Authorized Board Representative)	(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

MOUWASAT MEDICAL SERVICES COMPANY
(A SAUDI JOINT STOCK COMPANY)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)
FOR THE NINE-MONTH PERIOD ENDED 30 SEPTEMBER 2026
(Expressed in Saudi Riyals, unless otherwise stated)

	Note	**30 September 2026**	30 September 2025
		(Unaudited)	(Unaudited)
Cash flows from financing activities			
Proceeds from long-term borrowings	7	**388,000,000**	420,000,000
Repayment of long-term borrowings	7	**(149,532,761)**	(132,508,404)
Payment of lease liability	4.2	**(14,528,327)**	(4,074,141)
Dividends paid to shareholder		**(225,000,000)**	(400,000,000)
Dividends paid to non-controlling interest	13	**(12,250,000)**	(24,500,000)
Net cash outflow from financing activities		**(13,311,088)**	(141,082,545)
Net decrease in cash and cash equivalents		**(103,743,288)**	40,455,667
Cash and cash equivalents at the beginning of the period		**497,450,629**	426,574,756
Cash and cash equivalents at the end of the period		**393,707,341**	467,030,423
Significant non-cash transactions			
Transfer from advances to contractors and suppliers to property and equipment		**341,138,872**	111,335,138
Finance cost capitalized	3	**30,582,979**	24,119,258
Addition of right-of-use asset and lease liability	4	**38,765,013**	6,138,214
Re-assessment of right-of-use-asset and lease liability		**-**	13,254,589
Lease receivable	4	**-**	1,046,754

Nassir Alsubaei	Khalid Al Saleem	Adel Abou Hamra
(Chief Executive Officer)	(Authorized Board Representative)	(Chief Financial Officer)

The accompanying notes 1 through 19 on pages 7 to 20 form an integral part of these condensed consolidated interim financial statements.

1. ORGANIZATION AND ACTIVITIES

Mouwasat Medical Services Company ("the Company") is registered in Saudi Arabia under Commercial Registration number 2050032029 dated 12 Ramadan 1417H (corresponding to 21 January 1997). The Company was converted into a Saudi Joint Stock Company in accordance with Ministerial Resolution No. 1880 dated 4 Dhu-al-Hijja 1426H (corresponding to 4 January 2006). The unified number of the Company is 7001385033.

The Company through its multiple branches is engaged in the acquisition, management, operation and maintenance of hospitals, medical centers, drug stores, pharmacies and wholesale of medical equipment and drugs.

Branch	Commercial Registration Number	Date
Dammam	2050046891	18/09/1425H
Dammam	2050111494	20/04/1438H
Dammam	2050111780	25/05/1438H
Dammam	2050086573	27/11/1433H
Khobar	2051064380	12/09/1438H
Jubail	2055004626	09/03/1421H
Jubail	2055006727	19/09/1425H
Madinah	4650029967	06/05/1421H
Madinah	4650030759	11/11/1421H
Madinah	4650083001	18/01/1438H
Madinah	4650252425	19/05/1444H
Riyadh	1010295838	09/11/1431H
Yanbu	4700118283	04/06/1444H

Details regarding the Company's subsidiaries are as follows:

Name	Country of incorporation	Activities	Percentage %
Eastern Medical Services Company Limited	Saudi Arabia	Medical services	51%
Jeddah Doctors Company	Saudi Arabia	Medical services	51%
Modawaa and Rieaya Medical Company Limited	Saudi Arabia	Medical services	51%

Eastern Medical Services Company Limited is a limited liability company registered in the Kingdom of Saudi Arabia under commercial registration number 2051023824 dated 10 Ramadan 1420H (corresponding to 18 December 1999). This subsidiary is engaged in construction and operation of hospitals, dispensaries and special clinics. The unified number of the subsidiary is 7001401319.

Jeddah Doctors Company Limited ("JDC") (Saudi Closed Joint Stock Company) is registered in Kingdom of Saudi Arabia under commercial registration number 4030278617 dated 13 Muharram 1436H (corresponding to 6 November 2014). The subsidiary is engaged in general construction of non-residential buildings including (schools, hospitals, hotels etc.), demolition of buildings; purchase, sale and division of land and real estate, and off-plan sales activities; colleges and university institutes, hospitals, medical operation of hospitals. The unified number of the subsidiary is 7009433892.

Mouwasat Medical Services Company in partnership with Al Dawaa Medical Services Company, has established Modawaa and Rieaya Medical Company Limited ("Modawaa") a limited liability company within Kingdom of Saudi Arabia under commercial registration number 2051256627 dates 29 Dhu'al Qadah 1445H (corresponding to 6 June 2024) for the purpose of medical clinics activities. Modawaa's capital has been set at SR 1 million, with contributions divided as 51% for Mouwasat Medical Services Company and 49% for Al Dawaa Medical Services Company. The Company has control over Modawaa and classified it as a subsidiary. During the year ended 31 December 2025, additional capital contribution of SR 10 million was made by the shareholders as per their respective shareholding. The unified number of the subsidiary is 7039305979.

These condensed consolidated interim financial statements as at and for the nine-month period ended 30 September 2026 include all financial information of the branches of the Company and above-mentioned subsidiaries (together referred to as 'the Group').

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

2.1 Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" that is endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are issued by Saudi Organization for Chartered and Professional Accountants ("SOCPA").

The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual consolidated financial statements as at 31 December 2025 ("Last Annual Financial Statements"). However, changes in accounting policies, if any and selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.

2.2 Basis of preparation

These condensed consolidated interim financial statements are prepared using historical cost convention using the accrual basis of accounting except for employees benefit obligation which is measured at present value of the defined benefit obligation, financial assets at fair value through profit or loss which are measured at fair value and financial assets at fair value through other comprehensive income which are measured at fair value.

2.3 Functional and presentation currency

These condensed consolidated interim financial statements are presented in Saudi Riyals ("SR") which is also the functional and presentation currency of the Group. All values are rounded to the nearest one Riyal except where otherwise indicated.

2.4 Use of judgements and estimates

In preparing these condensed consolidated interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

2.5 Material accounting policies

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2025. A number of amendments to existing standards, as detailed in note 2.6 below, became effective from 1 January 2026 but they do not have a material effect on the condensed consolidated interim financial statements of the Group. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

2.6 New standards and amendments to existing standards

2.6.1 New and amended standards adopted by the Group

A number of amended standards became applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting these amended standards.

- Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 'Financial Instruments' and IFRS 7 'Financial Instruments: Disclosures', effective for annual periods beginning on or after 1 January 2026;

- Annual improvements to IFRS Accounting Standards – Amendments to: IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial Instruments: Disclosures and it's accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements, and IAS 7 Statement of Cash flows, effective for annual periods beginning on or after 1 January 2026; and

- Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7, effective for annual periods beginning on or after 1 January 2026.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES (CONTINUED)

2.6 New standards and amendments to existing standards (continued)

2.6.2 Amendments to existing standards issued but not yet effective

The amendments to existing standards that are issued, but not yet effective, up to the date of issuance of the condensed consolidated interim financial statements are disclosed below. The Group intends to adopt these amendments to existing standards, if applicable, when they become effective:

- IFRS 18 Presentation and Disclosure in Financial Statements, effective for annual periods beginning on or after 1 January 2027;
- IFRS 19 Subsidiaries with Public Accountability: Disclosures, effective for annual periods beginning on or after 1 January 2027;
- IAS 21 The Effects of Changes in Foreign Exchange Rates, effective for annual periods beginning on or after 1 January 2027;
- IAS 28 Investments in Associate and Joint Ventures, Effective for annual periods beginning on or after 1 January 2027;
- IFRS 20 Regulatory Assets and Regulatory Liabilities, Effective for annual periods beginning on or after 1 January 2029; and
- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture – Amendments to IFRS 10 and IAS 28, effective date deferred indefinitely.

The above-mentioned standards are not expected to have a significant or material impact on the condensed consolidated financial statements of the Group when they become effective except IFRS 18. Management is currently assessing the impact of IFRS 18 on its financial statements.

a) Structure of the Statement of Profit or Loss

IFRS 18 requires entities to classify all income and expenses into categories in the statement of profit or loss – namely operating, investing, financing, zakat income tax and discontinued operations. Classification of income and expenses depends on the main business activities of an entity. The Group has determined that it does not have a specified main business activity of investing in assets and/or providing financing to customers.

Neither net profit nor net assets will change as a result of the Group's adoption of IFRS 18. The Group will be required to present two newly defined subtotals, which are 'operating profit' and 'profit or loss before financing and income taxes'. However, operating profit subtotal differs from the current operating profit subtotal presented by the Group. Based on the information currently available, the Group expects changes to the current structure of the statement of profit or loss to result from the following:

- Interest income and expenses are generally included in finance income and finance costs under the Group's current accounting policy and are separately presented as finance income and finance costs respectively. IFRS 18 provides specific guidance on the income and expenses to be classified in the investing and financing categories.

- Interest cost on employee benefit obligations, which is currently presented within employee costs, will be classified and presented within finance costs.

b) Management-defined performance measures

Management-defined performance measures (MPMs) are subtotals of income and expenses used in public communications outside the financial statements that communicate users management's view of an aspect of the financial performance of the entity as a whole. The Group will be required to disclose specific information about MPMs in a single note in the financial statements.

The Group is in process to determine which public communications should be considered when identifying MPMs. MPMs relate to the same reporting period as the financial statements. Therefore, MPMs disclosed by the Group following adoption of IFRS 18 will be determined based on public communications issued by the Group relating to the 2027 interim reporting period.

2. BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES (CONTINUED)

2.6 New standards and amendments to existing standards (continued)

2.6.2 Amendments to existing standards issued but not yet effective (continued)

c) Principles of aggregation and disaggregation

IFRS 18 provides enhanced principles on how to group information in financial statements (i.e. the primary financial statements and the notes). It also introduces guidance on labelling and describing items presented in the primary financial statements or disclosed in the notes.

The Group is assessing the grouping of items on the basis of similar and dissimilar characteristics. Based on this assessment, it will present line items in the primary financial statements that provide useful structured summaries and disclose additional information in the note. The Group is also assessing line items currently labelled as 'other' and will use more informative labels.

d) Consequential amendments

IFRS 18 introduces consequential amendments to IAS 7, which require entities to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method. The Group currently uses profit for the year/period as the starting point of the reconciliation to cash flows from operating activities. Certain adjusting items included in the reconciliation will change as a result of the new starting point.

The consequential amendments also provide specific guidance on the classification of interest and dividend cash flows. Cash flows from interest received and interest and dividends paid will continue to be classified as investing activities and financing activities, respectively.

3. PROPERTY AND EQUIPMENT

3.1 Property and equipment comprise of the following:

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Land	**1,073,864,978**	828,833,760
Buildings	**1,457,723,422**	1,192,074,226
Building system and improvements	**582,955,804**	413,593,014
Medical equipment and tools	**522,593,528**	428,970,047
Furniture and fixture	**144,294,550**	101,383,519
Motor vehicle	**24,493,615**	17,196,292
Construction work in progress	**758,569,736**	989,249,291
	4,564,495,633	3,971,300,149

3.2 The movement of property and equipment is as follows:

	30 September 2026	30 September 2025
	(Unaudited)	(Unaudited)
Carrying value at the beginning of the period	**3,971,300,149**	3,509,651,696
Additions	**819,471,228**	538,894,544
Property and equipment written off, net	**(16,000)**	(1,612)
Disposals, net of accumulated depreciation	**(30,736,642)**	(713,309)
Depreciation for the period	**(195,523,102)**	(177,652,711)
Carrying value at the end of the period	**4,564,495,633**	3,870,178,608

As of 30 September 2026, plots of land amounting to SR 30.8 million (31 December 2025: SR 52.9 million) have been pledged as security against term loans from Ministry of Finance. During 2025, the Group has fully paid the outstanding loan amount related to two regions and applied for release of mortgage against lands having carrying amount of SR 22.1 million. During the period ended 30 September 2026, the mortgage on the lands have been successfully released.

Finance costs capitalized during the nine-month period ended 30 September 2026 amounted to SR 30.58 million (30 September 2025: SR 24.12 million).

3. PROPERTY AND EQUIPMENT (CONTINUED)

3.3 Construction work-in-progress

The carrying value in note 3.1 includes construction work-in-progress amounting to SR 758.57 million (31 December 2025: SR 989.25 million). It represents the costs incurred to construct new hospitals and expansion of existing hospitals, which is currently in work-in-progress. During the period ended 30 September 2026, the Group completed the construction of its hospital located in Yanbu. Accordingly, costs previously recorded under capital work-in-progress were transferred to property and equipment upon commencement of operations on 1 February 2026 amounting to SR 407.9 million.

4. LEASES

a) Leases as lessee

The Group has contracted for lease of building in Madinah having a lease period of 11 years in 2019 with an option to renew thereafter on mutual consent. Lease payments agreed at the time of inception of lease may change during the tenure of agreement based on mutual consent of both parties.

During 2024, the Group recognised lease of land for the construction of hospital in Yanbu for 43 years for the agreement entered during 2022, with an option to renew thereafter on mutual consent. Lease payments are agreed at the time of inception and are fixed during the tenure of the agreement.

During 2025, the Group has recognised leases of land for the construction of a polyclinic in Jubail for 20-30 years and a building in Dammam to operate a clinic for 10 years with an option to renew the leases thereafter on mutual consent. During the period ended 30 September 2026, the Group has recognised leases of staff accommodation.

4.1 Right-of-use-assets

	30 September 2026	30 September 2025
	(Unaudited)	(Unaudited)
Carrying value at the beginning of the period	**36,614,738**	20,090,410
Additions	**38,765,013**	6,138,214
Effect of re-assessment of lease term	**-**	13,254,589
Depreciation expense	**(9,395,808)**	(2,497,936)
De-recognition of right of use assets	**-**	(266,386)
Carrying value at the end of the period	**65,983,943**	36,718,891

4.2 Lease liabilities

	30 September 2026	30 September 2025
	(Unaudited)	(Unaudited)
Carrying value at the beginning of the period	**41,421,180**	23,295,907
Addition	**38,765,013**	6,138,214
Effect of re-assessment of lease term	**-**	13,254,589
Interest expense	**2,922,727**	1,429,206
Payments	**(14,528,327)**	(4,074,141)
Carrying value at the end of the period	**68,580,593**	40,043,775

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Current portion	**15,917,340**	4,768,426
Non-current portion	**52,663,253**	36,652,754
	68,580,593	41,421,180

4. LEASES (CONTINUED)

b) Leases as lessor

During 2025, the Group has sub-leased Madinah building that has been presented as a right-of-use asset. The Group derecognized the right-of-use asset pertaining to the building amounting to SR 266,386.

	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Carrying value at the beginning of the period	**1,003,793**	**-**
Additions during the period	**-**	1,046,754
Interest income	**23,275**	11,015
Lease rental received	**(141,000)**	(70,500)
Carrying value at the end of the period	**886,068**	987,269

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Current portion	**84,176**	141,000
Non-current portion	**801,892**	862,793
	886,068	1,003,793

5. ACCOUNTS RECEIVABLE

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Accounts receivable – trade	**1,102,441,999**	955,644,421
Less: allowance for expected credit losses	**(66,318,906)**	(49,803,440)
	1,036,123,093	905,840,981

Movement in the allowance for expected credit losses is as follows:

	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Balance at the beginning of the period	**49,803,440**	92,414,684
Allowance / (reversal) for expected credit losses during the period	**16,960,367**	(15,740,995)
Written off	**(444,901)**	(32,754,356)
Balance at the end of the period	**66,318,906**	43,919,333

6. SHARE CAPITAL

The authorized, issued and fully paid share capital of the Company is divided into 200 million shares (31 December 2025: 200 million shares) of SR 10 each.

7. LONG TERM BORROWINGS

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Current		
Loans from commercial banks	**176,264,957**	185,617,569
Loans from Ministry of Finance	**5,303,650**	5,303,650
	181,568,607	190,921,219
Non- current		
Loans from commercial banks	**951,933,768**	698,810,267
Loans from Ministry of Finance	**53,036,492**	58,340,142
	1,004,970,260	757,150,409

Loans from Commercial Banks
The Group obtained Islamic loan facilities from various local commercial banks. These loans are secured by promissory notes and assignment of insurance and contract proceeds. These facilities are subject to commission rates based on Saudi Arabia Interbank Offered Rate "SIBOR" plus an agreed margin.

During the period, the Group obtained loan amounting to SR 388 million (30 September 2025: SR 420 million) and repaid loans amounting to SR 149.53 million (30 September 2025: SR 132.51 million).

Loans from Ministry of Finance
The Group obtained loan facilities of SR 147.3 million from the Ministry of Finance for expansion and building of new hospitals and the purchase of medical equipment. The loans are secured by mortgage on the Group's plots of land and are repayable on equal annual instalments. These loans do not carry any financial charges. During the period, the Group repaid loans amounting to SR 5.3 million (30 September 2025: SR 5.3 million).

As at 30 September 2026, the Group had SR 332 million of unutilized facilities available for drawdown from total facilities of SR 2,206 million (31 December 2025: SR 820 million of unutilized facilities available for drawdown from total facilities of SR 2,490 million).

The Group is required to comply with certain covenants under the loan facility agreements. The covenants are monitored on a monthly basis by management and in case of potential breach, actions are taken by management to ensure compliance. The Group was in compliance with financial covenants as of 30 September 2026 and 31 December 2025. Aggregate maturities are as follows:

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Within one year	**181,568,607**	190,921,219
Later than one year but not later than five years	**858,159,479**	652,828,517
Later than five years	**146,810,781**	104,321,892
	1,186,538,867	948,071,628

8. ZAKAT

The movement in Zakat provision is:

	30 September 2026	30 September 2025
	(Unaudited)	(Unaudited)
Balance at the beginning of the period	**34,988,175**	34,117,865
Charge:		
Current period	**17,572,551**	24,272,490
Prior period reversal	**(8,121,529)**	(678,224)
	9,451,022	23,594,266
Paid during the period	**(23,557,210)**	(30,263,885)
Balance at the end of the period	**20,881,987**	27,448,246

8. ZAKAT (CONTINUED)

Mouwasat Medical Services Company
The Company submitted its Zakat returns up to the year ended 31 December 2025, settled Zakat as per the return and obtained the required certificates and official receipts. The assessments for the years up to 2016 were finalized and settled in 2018. Zakat, Tax and Custom Authority ("ZATCA") raised queries for years 2017 and 2018 and the Company has provided the relevant information. According to ZATCA portal, the inquiry case for these years was closed and ZATCA did not raise any Zakat differences. ZATCA raised assessments for the years 2019 and 2020 with a total liability of SR 7.3 million. Company has submitted an objection against ZATCA's assessment for the year 2019 and 2020 and subsequent to the objection, ZATCA issued a revised assessment with a total liability of SR 5.2 million, on which the Company filed an appeal against the rejection with the Committee for Resolution of Tax Violations and Disputes "CRTVD" through the General Secretariat of Tax Committees "GSTC" portal. The CRTVD has issued its decision where it has rejected the Company appeal. Subsequently, the Company has appealed the CRTVD's decision with the Appellate Committee of Tax Violations and Dispute Resolution "ACTVDR". During 2024, the decision was issued in favor of ZATCA. During the year ended 31 December 2025, the Company paid SR 4.59 million against the 2019 and 2020 assessments. However, the Company is awaiting a final decision from ZATCA. The Company received an assessment for the years 2021 and 2022 amounting to SR 2.4 million which has been finalized and paid. The Company has received the final assessment for the year 2023, accepting the filed return with no additional zakat liability. During the period ended 30 September 2026, the Company received final assessment from ZATCA for 2024 which was finalized and paid with additional liability of SR 18,795. The Company kept additional zakat provisions related to prior years based on the prior year zakat assessments. However, based on the finalization of the 2024 zakat assessment the Company has reversed additional zakat provision of SR 8.1 million. During the period ended 30 September 2026, Company finalized the Zakat assessment for the year 2025 with no additional zakat liability.

Eastern Medical Services Company Limited
The subsidiary has submitted its Zakat returns up to the year ended 31 December 2025, settled Zakat as per the returns and obtained the required certificates and official receipts. The assessments for the years from 2013 to 2016 and for the year 2018 were finalized and settled in 2018. ZATCA raised an assessment for the year 2019 amounting to SR 0.663 million and the Company has submitted an objection against ZATCA's assessment for the year 2019. ZATCA issued a revised assessment rejecting the Company appeal. The Company filed an appeal against the rejection with the CRTVD through the GSTC portal. During the period, CRTVD issued its decision regarding the Company's appeal and partially accepted certain contentions of the Company. Subsequently, the Company appealed the CRTVD's decision with the ACTVDR. During 2025, the decision was issued in favor of ZATCA, and the Company paid an amount of SAR 594,623 as final settlement. During the period ended 30 September 2025, the Company received Zakat assessment for the year 2022. Subsequent to the period ended 30 September 2026, final notice was issued by ZATCA for SR 0.19 million. Company does not agree with the assessment and will formally submit an objection against the final assessment notice by ZATCA. The assessments for the years 2023 to 2025 are still under review by ZATCA.

Jeddah Doctor Company
The subsidiary submitted the Zakat return up to the year ended 31 December 2025, settled Zakat as per the returns and obtained the required certificates and official receipts. The subsidiary has not received any assessments from ZATCA since inception.

Modawaa and Rieaya Medical Company Limited
The subsidiary has submitted the Zakat return for the year ended 31 December 2025, settled Zakat as per the returns and obtained the required certificates and official receipts. The subsidiary has not received any assessments from ZATCA since inception.

9. REVENUE

The Group generates revenue primarily from:
- Services relating to inpatient and outpatient; and
- Sale of pharmaceutical goods.

Disaggregation of revenue
In the following table, revenue from contracts with customers is disaggregated by service lines and timing of revenue recognition. All revenues are generated within the Kingdom of Saudi Arabia.

	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Revenue by service lines		
Medical services	**2,203,459,707**	1,987,753,053
Pharmaceutical sales	**363,146,752**	350,273,693
	2,566,606,459	2,338,026,746
Timing of revenue recognition		
Medical services and pharmaceuticals sales transferred at a point in time	**1,424,047,934**	1,338,903,623
Medical services transferred over time	**1,142,558,525**	999,123,123
	2,566,606,459	2,338,026,746

The following table provides information about contract assets and refund liability from contracts with customers:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Refund liability (note 9.1)	**197,673,611**	179,041,660
Contract assets (note 9.2)	**6,529,277**	5,873,388

9.1 Refund liability
Certain contracts provide discounts comprise retrospective volume discounts granted to third-party payers (insurance and other companies) on attainment of certain admission levels / certain levels of patient visits. The retrospective volume discounts give rise to variable consideration. Variable consideration is recognized as revenue to the extent that it is highly probable that it will not reverse. Discounts are accrued over the course of the period based on the estimated level of business using the single most likely amount method. This is adjusted at the end of the period to reflect actual volumes. Volume discounts are recorded as a reduction in revenue and liabilities are created based on these estimates.

9.2 Contract assets
Contract assets are related to in-patients who were provided with services during the reporting period but were not discharged or billed as of the reporting date. Contract assets are included as part of Advances, prepayments and other current assets.

10. RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include Company's shareholders, associated companies and their shareholders, key management personnel, Board of Directors and entities controlled, jointly controlled or significantly influenced by such parties. Terms and conditions of these transactions are approved by the Group's management. During the period, the Group transacted with the following related parties:

Related Party	**Relationship**
Al-Mouwasat International Company	Owned by shareholder
AdVision Media Solution	Entity with significant influence

10. RELATED PARTY TRANSACTIONS AND BALANCES (CONTINUED)

Related Party	Nature of transaction	For the nine-month period ended 30 September	
		2026	2025
Al-Mouwasat International Company	- Purchases	**1,507,746**	21,100,580
	- Other services	**2,548,800**	2,954,237
AdVision Media Solution	- Advertisement services	**28,736,894**	22,908,844

The breakdown of the amounts due to / advance to related parties are as follows:

a) Due to related parties

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
Al-Mouwasat International Company	**331,350**	464,885
AdVision Media Solution	**-**	2,482,477
	331,350	2,947,362

b) Advance to a related party

	30 September 2026	31 December 2025
	(Unaudited)	(Audited)
AdVision Media Solution	**3,859,810**	-

Amounts due to and advance to related parties principally include balances related to the above-mentioned transactions. Outstanding balances at the reporting date are unsecured, interest free and payable within credit period in the ordinary course of business. Prices and terms of payment of the above transactions are approved by the Group's management.

c) Compensation to key management personnel

The remuneration of directors and other key management personnel during the period was as follows:

	Nine-month period ended 30 September 2026	Nine-month period ended 30 September 2025
	(Unaudited)	(Unaudited)
Salary and allowances	**18,049,500**	16,612,500
Incentives and other benefits	**17,630,889**	12,176,971
	35,680,389	28,789,471

The remuneration of directors and key executives is determined by the remuneration committee considering the performance of individuals and market trends. The Board of Directors' fee of SR 6.7 million (30 September 2025: SR 5.7 million) has been included as part of key management personnel remuneration.

11. EARNINGS PER SHARE

Basic and diluted earnings per share are calculated by dividing the net income for the period attributable to the shareholders of the Company by the weighted average number of outstanding shares during the period. As the Company does not have any dilutive potential shares, the diluted earnings per share are the same as basic earnings per share.

	For the three-month period ended		For the nine-month period ended	
	30 September 2026	30 September 2025	**30 September 2026**	30 September 2025
	(Unaudited)	(Unaudited)	**(Unaudited)**	(Unaudited)
Profit for the period attributable to the shareholders of the Company	**188,013,890**	199,657,372	**600,396,339**	583,670,787
Weighted average number of outstanding shares during the period	**200,000,000**	200,000,000	**200,000,000**	200,000,000
Basic and diluted earnings per share attributable to the shareholders of the Company	**0.94**	1.00	**3.00**	2.92

12. CONTINGENCIES AND COMMITMENTS

12.1 As at 30 September 2026, the Group's bankers have given guarantees, on behalf of the Group, amounting to SR 37.11 million (31 December 2025: SR 29.8 million) mainly in respect of performance guarantees to customers.

12.2 As at 30 September 2026, the Group's capital commitments amounted to SR 370.87 million (31 December 2025: SR 239.47 million) relating to certain expansion projects.

12.3 As at 30 September 2026, the Group has outstanding letter of credits amounting to SR 51.43 million (31 December 2025: SR 94.41 million).

13. DIVIDENDS

The shareholders of the Company during the Ordinary General Assembly Meeting (First Meeting) held on 17 Dhual Qaddah 1447H (corresponding to 4 May 2026) authorized the Board of Directors to distribute interim dividends to the Company's shareholders on a semi-annual or quarterly basis for the fiscal year 2026.

Subsequent to the period ended 30 September 2026, the Board of Directors at their meeting held on 24 Rabi Al Thani 1448H (corresponding to 5 October 2026) declared a cash dividend of SR 1 per share amounting to SR 200 million for the first half of the year ended 31 December 2026G. The consolidated interim financial statements for the period ended 30 September 2026 do not include the effect of the aforementioned proposed dividend.

The Board of Directors at their meeting held on 11 Ramadan 1447H (corresponding to 28 February 2026) proposed a cash dividend of SR 1.125 per share amounting to SR 225 million for the second half of the year ended 31 December 2025G which was subsequently approved by the shareholders in the Annual General Meeting held on 17 Dhul Qaddah 1447H (corresponding to 4 May 2026G).

The Board of Directors at their meeting held on 22 Jumada Al-Akhirah1446H (corresponding to 23 December 2024) proposed a cash dividend of SR 2 per share amounting to SR 400 million for the year ended 31 December 2024G which was subsequently approved by shareholders in General Assembly Meeting held on 7 Dhual Qa'dah 1446H (corresponding to 5 May 2025G).

14. SEGMENT INFORMATION

The Board of Directors monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on revenue and gross profit and is measured consistently in the interim condensed consolidated financial statements.

The Group's operations consist mainly of medical services and pharmaceuticals products segment.

Operating segments:
For management purposes, the Group is organized into business units based on its products and services and has two reportable segments:

- Medical Services segment: Inpatient and outpatient services.
- Pharmaceuticals'.

No operating segments have been aggregated to form the above reportable operating segments.

	Medical Services	Pharmaceuticals	Total
For the nine-month period ended 30 September 2026 (unaudited)			
Revenue	**2,203,459,707**	**363,146,752**	**2,566,606,459**
Gross profit	**925,979,945**	**117,119,417**	**1,043,099,362**
For the nine-month period ended 30 September 2025 (unaudited)			
Revenue	1,987,753,053	350,273,693	2,338,026,746
Gross profit	873,098,297	110,315,788	983,414,085
As at 30 September 2026 (unaudited)			
Total assets	**6,372,933,324**	**335,417,544**	**6,708,350,868**
Total liabilities	**2,174,119,403**	**228,222,479**	**2,402,341,882**
As at 31 December 2025 (audited)			
Total assets	5,686,954,035	299,313,370	5,986,267,405
Total liabilities	1,869,485,620	196,244,347	2,065,729,967

Geographical segments:
All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

The accounting policies of the reportable segments are the same as the Group's accounting policies. Segment profit represents the profit earned by each segment without allocation of the share of profits of associates, central administration costs including directors' salaries, profit from term deposit, non-operating gains and losses in respect of financial instruments and finance costs. This is the measure reported to the Board of Directors for the purpose of resource allocation and assessment of segment performance.

15. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT

The Group's principal financial assets include cash and cash equivalents, accounts receivable and certain other receivables that arise directly from its operations. The Group's principal financial liabilities comprise long-term borrowings and accounts payable, due to related parties and other payables. The main purpose of these financial liabilities is to finance the Group's operations.

15. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (CONTINUED)

Fair values hierarchy
All financial instruments for which fair value is recognized or disclosed are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:

Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognized at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

There were no changes in the Group's valuation processes, valuation techniques, and types of input used in the fair value measurements during the period.

Accounting classifications and fair values
The following table shows the carrying value of financial assets and financial liabilities. All financial assets and financial liabilities of the Group are categorized as being held at amortized cost. Management believes that the fair values of the Group's financial assets and liabilities are not materially different from their carrying values.

Particulars	**30 September 2026** **Carrying value (Amortized cost)** **(Unaudited)**	31 December 2025 Carrying value (Amortized cost) (Audited)
Financial assets not measured at fair value		
Accounts receivable (note 5)	**1,036,123,093**	905,840,981
Contract assets (note 9.2)	**6,529,277**	5,873,388
Cash and cash equivalents	**393,707,341**	497,450,629
Other current assets	**13,296,487**	23,926,382
Lease receivable (note 4(b))	**886,068**	1,003,793
Advance to a related party (note 10)	**3,859,810**	-
Total	**1,454,402,076**	1,434,095,173

Particulars	**30 September 2026** **Carrying value (Amortized cost)** **(Unaudited)**	31 December 2025 Carrying value (Amortized cost) (Audited)
Financial liabilities not measured at fair value		
Loans and borrowings (note 7)	**1,186,538,867**	948,071,628
Lease liabilities (note 4.2)	**68,580,593**	41,421,180
Accounts payable	**359,892,042**	318,801,368
Due to related parties (note 10)	**331,350**	2,947,362
Retention payable	**57,050,955**	67,316,867
Refund liability (note 9)	**197,673,611**	179,041,660
Other current liabilities	**186,956,259**	175,954,020
Total	**2,057,023,677**	1,733,554,085

15. FINANCIAL INSTRUMENTS – FAIR VALUE AND RISK MANAGEMENT (CONTINUED)

As at the reporting date all financial assets and financial liabilities are measured at amortized cost. The carrying value of the financial assets and financial liabilities of the Group approximate their fair value.

Risk management activities
The Group's financial risk management objectives and policies are consistent with those disclosed in the last annual consolidated financial statements as at and for the year ended 31 December 2025.

16. OTHER RESERVE

In accordance with the By-laws of the Company, 10% of the profit for the year is required to be transferred to the other reserve until the balance in the reserve equals 30% of the capital.

17. SUBSEQUENT EVENTS

Subsequent to the period ended 30 September 2026, a commercial lawsuit was filed against the Company before the Commercial Court in Dammam. The plaintiff seeks an order requiring the Company to establish the transfer of the plaintiff's entire shareholding in Jeddah Doctors Company, a subsidiary of the Company, representing 32.42% of the subsidiary's share capital, and to pay SR 335.4 million as consideration for the transfer of those shares to the Company.

Based on management's assessment and the opinion of external legal counsel, it is not considered probable, at this stage, that the court will grant the plaintiff's claim. Accordingly, no provision has been recognized in these condensed interim financial statements in respect of this matter. The Company will continue to monitor the proceedings through its external legal counsel.

There were no significant events that occurred subsequent to 30 September 2026, except as mentioned otherwise in these condensed interim consolidated financial statements, that would have a material impact on the financial position and financial performance of the Group.

18. COMPARITIVE FIGURES

During the year ended 31 December 2025, management has reclassified the employee costs among cost of operations, general and administration expenses and selling and distribution expenses for better presentation.

The comparatives as at and for the period ended 30 September 2025 have been reclassified as follows to confirm with current period presentation.

Description	Reclassified from	Reclassified to	For the three-month period ended	For the nine-month period ended
			Amount (SR)	Amount (SR)
Employee costs	General and administration expenses	Cost of operations	**14,942,408**	**43,793,924**
Employee costs	Selling and distributing expenses	General and administration expenses	**19,182,761**	**57,471,191**

19. APPROVAL OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

These condensed consolidated interim financial statements have been approved on behalf of Board of Directors on 24 Jumada Al Oula 1448H, corresponding to 4 November 2026G.